Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
105M
-
Number of holders
-
203
-
Total 13F shares, excl. options
-
82.5M
-
Shares change
-
+425K
-
Total reported value, excl. options
-
$428M
-
Value change
-
+$73.6M
-
Put/Call ratio
-
1.31
-
Number of buys
-
106
-
Number of sells
-
-94
-
Price
-
$5.19
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q3 2024
268 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2024.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 203 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 82.5M shares
of 105M outstanding shares and own 78.84% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (8.73M shares), VANGUARD GROUP INC (5.73M shares), FRANKLIN RESOURCES INC (4.78M shares), FIL Ltd (4.19M shares), ALPINE ASSOCIATES MANAGEMENT INC. (4.16M shares), ALLIANCEBERNSTEIN L.P. (3.26M shares), Magnetar Financial LLC (2.5M shares), TANG CAPITAL MANAGEMENT LLC (2.5M shares), STATE STREET CORP (2.43M shares), and WATER ISLAND CAPITAL LLC (2.38M shares).
This table shows the top 203 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.